Why Hims & Hers Stock Rebounded on Wednesday

Hims & Hers (NYSE: HIMS) stock was a heartening comeback story on Wednesday, following something of a rout earlier in the week. Several analysts raised their price targets on the specialty healthcare company on that slump, which helped Hims & Hers recover by more than 5% in mid-week action. That was more than good enough to top the S&P 500 index's essentially flat performance.

Post-slump pundit boosts

The source of investor bearishness in previous days was Hims & Hers' announcement on Monday that it might halt sales of a highly popular product -- compound versions of semaglutide, the white-hot molecule used in Novo Nordisk's Wegovy. Hims & Hers had been allowed to sell semaglutide due to a shortage in the market. However, the U.S. Food and Drug Administration (FDA) has declared the shortage over.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

Investors can be rather unforgiving when a company even hints at abandoning a hot product or service. So not surprisingly, they traded aggressively out of Hims & Hers when disseminating the news.

In reaction to this, several analysts tracking the stock effectively judged this to be an overreaction. After market close on Tuesday, TD Cowen's Jonna Kim just as aggressively raised her price target on the stock, to $44 per share from $28. She maintained her buy recommendation because, according to reports, she still feels the company has fine potential even without semaglutide.

Joining the club

Joining Kim in the Hims & Hers price target boost party were Piper Sandler's Korinne Wolfmeyer and Truist's Jailendra Singh, both of whom made substantial raises. The two remained cautious about the company's prospects, however, as they held fast to their equivalents of hold recommendations.

The optimism is understandable, as Hims & Hers is an innovative healthcare company that probably doesn't need semaglutide to grow and succeed. Still, as a wildly popular product its loss is going to be felt, and not comfortably -- particularly since the company recently invested quite a bit of capital to publicize this business.

Should you invest $1,000 in Hims & Hers Health right now?

Before you buy stock in Hims & Hers Health, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hims & Hers Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $776,055!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.

Learn more »

*Stock Advisor returns as of February 24, 2025

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.